# US 2017/0362290 A1 · Il-17a-binding polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362290 A1
- Document ID: US20170362290A1
- Status: Published application
- Kind: A1
- Application number: 15/538,890
- Filed: 2016-01-12
- Published: 2017-12-21
- Earliest claimed: 2015-01-12
- Assignees: Affibody AB
- Applicants: Affibody AB
- Inventors: Fredrik Frejd; Joachim Feldwisch; Susanne Klint; Lindvi Gudmundsdotter
- Web page: https://patentgrep.com/patent/US20170362290A1

## CPC

- C07K 14/54: Interleukins [IL]
- A61K 38/20: Interleukins [IL]
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/745: Blood coagulation or fibrinolysis factors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EX2DX4AX6X7EIX10X11 LPNL X16X17X18QX20X21AFIX25 X26LX28X29. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and/or therapeutic agent.

## Claims

### Claim 1

An IL-17A binding polypeptide, comprising an IL-17A binding motif BM, which motif consists of an amino acid sequence selected from:
i) EX2DX4AX6X7EIX10X11LPNL X16X17X18QX20X21AFIX25 X26LX28X29
wherein, independently from each other,
X2 is selected from A, H, M and Y;
X4 is selected from A, D, E, F, K, L, M, N, Q, R, S and Y;
X6 is selected from A, Q and W;
X7 is selected from F, I, L, M, V, W and Y;
X10 is selected from A and W;
X11 is selected from A, D, E, F, G, L, M, N, Q, S, T and Y;
X16 is selected from N and T;
X17 is selected from H, W and Y;
X18 is selected from A, D, E, H and V;
X20 is selected from A, G, Q, S and W;
X21 is selected from A, D, E, F, H, K, N, R, T, V, W and Y;
X25 is selected from A, D, E, G, H, I, L, M, N, Q, R, S, T and V;
X26 is selected from K and S;
X28 is selected from I, L, N and R; and
X29 is selected from D and R;
and
ii) an amino acid sequence which has at least 89% identity to the sequence defined in i).

### Claim 2 (depends on 1)

An IL-17A binding polypeptide according to claim 1, wherein, in sequence i),
X2 is selected from A, H and M;
X4 is selected from A, D, E, F, L, M, N, Q, R and Y;
X11 is selected from A, D, E, F, G, L, M, N, S, T and Y;
X18 is selected from A, D, E and V;
X20 is selected from A, G, Q and W;
X21 is selected from E, F, H, N, R, T, V, W and Y;
X25 is selected from A, D, E, G, H, I, L, N, Q, R, S, T and V; and
X28 is selected from I, N and R.

### Claim 3 (depends on 2)

An IL-17A binding polypeptide according to claim 2, wherein, in sequence i),
X16 is T;
X17 is W;
X21 is selected from E, F, H, W, T and Y;
X25 is selected from A, D, E, G, H, I, L, N, Q, R, S and T;
X26 is K; and
X29 is D.

### Claim 4 (depends on 1)

An IL-17A binding polypeptide according to claim 1, wherein sequence i) is the sequence from position 8 to position 36 in a sequence selected from the group consisting of SEQ ID NO:1-1216.

### Claim 5 (depends on 1, 2, 3, 4)

An IL-17A binding polypeptide according to claim 1, which comprises an amino acid sequence binding module, BMod, selected from:
iii) K-[BM]-DPSQS XaXbLLXc EAKKL XdXeXfQ;
wherein
[BM] is an IL-17A binding motif as defined in any one of claims 1-4 provided that X29 is D;
Xa is selected from A and S;
Xb is selected from N and E;
Xc is selected from A, S and C;
Xd is selected from E, N and S;
Xe is selected from D, E and S;
Xf is selected from A and S; and
iv) an amino acid sequence which has at least 85% identity to a sequence defined by iii).

### Claim 6 (depends on 5)

An IL-17A binding polypeptide according to claim 5, wherein said sequence iii) is the sequence from position 7 to position 55 in a sequence selected from the group consisting of SEQ ID NO:1-1216.

### Claim 7 (depends on 1, 5, 6)

An IL-17A binding polypeptide according to claim 1, which comprises an amino acid sequence selected from:
vii) YA-[BMod]-AP;
wherein [BMod] is an IL-17A binding module as defined in any one of claims 5-6; and
viii) an amino acid sequence which has at least 86% identity to a sequence defined by vii).

### Claim 8 (depends on 1, 2, 3, 4)

An IL-17A binding polypeptide according to claim 1, which comprises an amino acid sequence selected from:
xiii)
VDAKYAK-[BM]-DPSQSSELLSEAKKLNDSQAPK;
wherein [BM] is an IL-17A binding motif as defined in any one of claims 1-4; and
xiv) an amino acid sequence which has at least 86% identity to the sequence defined in xiii).

### Claim 9 (depends on 8)

An IL-17A binding polypeptide according to claim 8, wherein sequence xiii) is selected from SEQ ID NO:1-1216.

### Claim 10 (depends on 1, 2, 3, 4)

An IL-17A binding polypeptide according to claim 1, which comprises an amino acid sequence selected from:
xv)
AEAKYAK-[BM]-DPSQSSELLSEAKKLNDSQAPK;
wherein [BM] is an IL-17A binding motif as defined in any one of claims 1-4; and
xvi) an amino acid sequence which has at least 86% identity to the sequence defined in xv).

### Claim 11 (depends on 10)

An IL-17A binding polypeptide according to claim 10, wherein sequence xv) is selected from SEQ ID NO:1217-1222.

### Claim 12 (depends on 1)

An IL-17A binding polypeptide according to claim 1, which is capable of binding to IL-17A such that the KD value of the interaction is at most 1×10−6 M, such as at most 1×10−7 M, such as at most 1×10−8 M, such as at most 1×10−9 M.

### Claim 13 (depends on 1)

A Fusion protein or conjugate comprising
a first moiety consisting of an IL-17A binding polypeptide according to claim 1; and
a second moiety consisting of a polypeptide having a desired biological activity.

### Claim 14 (depends on 1, 13)

A Complex, comprising at least one IL-17A binding polypeptide according to claim 1 or at least one fusion protein or conjugate according to claim 13, and at least one antibody or an antigen binding fragment thereof.

### Claim 15 (depends on 1)

A Polynucleotide encoding a polypeptide according to claim 1.

### Claim 16 (depends on 1)

A Composition comprising an IL-17A binding polypeptide, fusion protein, conjugate or complex according to claim 1 and at least one pharmaceutically acceptable excipient or carrier.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A medicament, diagnostic agent or prognostic agent comprising an IL-17A binding polypeptide, fusion protein, conjugate or complex or composition according to claim 1.
